Similar articles for PMID: 1378887

Year	Number of Results
1987	1
1989	4
1991	2
1992	6
1993	4
1994	5
1995	4
1996	5
1997	6
1998	8
1999	3
2000	2
2001	7
2002	9
2003	4
2004	9
2005	6
2006	9
2007	11
2008	7
2009	13
2010	5
2011	7
2012	7
2013	6
2014	14
2015	8
2016	6
2017	6
2018	2
2019	1
2020	2
2021	3
2022	1
2024	0

1

Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer.

Farhanghi M, Holmes RA, Volkert WA, Logan KW, Singh A. Farhanghi M, et al. J Nucl Med. 1992 Aug;33(8):1451-8. J Nucl Med. 1992. PMID: 1378887 Free article.

2

Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases.

Bayouth JE, Macey DJ, Kasi LP, Fossella FV. Bayouth JE, et al. J Nucl Med. 1994 Jan;35(1):63-9. J Nucl Med. 1994. PMID: 7505819 Free article. Clinical Trial.

3

A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.

Turner JH, Claringbold PG, Hetherington EL, Sorby P, Martindale AA. Turner JH, et al. J Clin Oncol. 1989 Dec;7(12):1926-31. doi: 10.1200/JCO.1989.7.12.1926. J Clin Oncol. 1989. PMID: 2585026

4

The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.

Liepe K, Runge R, Kotzerke J. Liepe K, et al. J Cancer Res Clin Oncol. 2005 Jan;131(1):60-6. doi: 10.1007/s00432-004-0625-0. Epub 2004 Sep 22. J Cancer Res Clin Oncol. 2005. PMID: 15449184 Clinical Trial.

5

Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study.

Yuan J, Liu C, Liu X, Wang Y, Kuai D, Zhang G, Zaknun JJ. Yuan J, et al. Clin Nucl Med. 2013 Feb;38(2):88-92. doi: 10.1097/RLU.0b013e318279bf4d. Clin Nucl Med. 2013. PMID: 23334120 Clinical Trial.

6

Clinical Efficacy and Safety Comparison of 177Lu-EDTMP with 153Sm-EDTMP on an Equidose Basis in Patients with Painful Skeletal Metastases.

Thapa P, Nikam D, Das T, Sonawane G, Agarwal JP, Basu S. Thapa P, et al. J Nucl Med. 2015 Oct;56(10):1513-9. doi: 10.2967/jnumed.115.155762. Epub 2015 Aug 27. J Nucl Med. 2015. PMID: 26315829 Free article. Clinical Trial.

7

Samarium-153-EDTMP biodistribution and dosimetry estimation.

Eary JF, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M, Hartnett S, Ferency S, Addison SJ, Appelbaum F, et al. Eary JF, et al. J Nucl Med. 1993 Jul;34(7):1031-6. J Nucl Med. 1993. PMID: 7686217 Free article. Clinical Trial.

8

Samarium-153 EDTMP therapy of disseminated skeletal metastasis.

Turner JH, Martindale AA, Sorby P, Hetherington EL, Fleay RF, Hoffman RF, Claringbold PG. Turner JH, et al. Eur J Nucl Med. 1989;15(12):784-95. doi: 10.1007/BF00255498. Eur J Nucl Med. 1989. PMID: 2483138

9

Samarium for osteoblastic bone metastases and osteosarcoma.

Anderson P. Anderson P. Expert Opin Pharmacother. 2006 Aug;7(11):1475-86. doi: 10.1517/14656566.7.11.1475. Expert Opin Pharmacother. 2006. PMID: 16859431 Review.

10

Our experience on pain palliation of bone metastasis with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study.

Montesano T, Giacomobono S, Acqualagna G, Colandrea M, Di Nicola A, Travascio L, Giancamerla M, D'Apollo R, Toteda M, Ugolini F, Filesi M, Ronga G. Montesano T, et al. Clin Ter. 2009;160(3):193-9. Clin Ter. 2009. PMID: 19756320

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

176 results

Results by year